Vactech has developed virus-like particle technology (VLP) which can be used for multiple purposes (IMAVAC™). These particles are like viruses which have been constructed from recombinant proteins but lack the genome and are therefore not infectious. IMAVAC™ technology is based on the enterovirus backbone.

Preclinical studies have shown that these particles elicit strong immune responses and work as well as traditional vaccines. This technology offer also possibilities to develop immunomodulators which can be used for the prevention and treatment of allergic and autoimmune diseases.